Entering text into the input field will update the search result below

EC OK's Merck's Keytruda in first-line lung cancer

Mar. 14, 2019 7:00 AM ETMerck & Co., Inc. (MRK) Stock, CELG StockBy: Douglas W. House, SA News Editor4 Comments
  • As expected, the European Commision approves Merck's (NYSE:MRK) Keytruda (pembrolizumab), combined with carboplatin and Celgene's (NASDAQ:CELG) Abraxane (paclitaxel protein-bound), for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC).
  • In early February, the advisory group CHMP adopted a positive opinion backing approval.

Recommended For You

Related Stocks

SymbolLast Price% Chg
CELG
--
MRK
--